Page 7 - Polypid Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator: Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. [Operator Instructions].

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage bio

PolyPid (NASDAQ:PYPD – Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, August 9th. Parties that wish to listen to the company’s conference call can do so using this link. PolyPid (NASDAQ:PYPD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 10th. The […]

Acutus Medical (NASDAQ:AFIB – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Analyst Recommendations This is a summary of recent […]

PolyPid Ltd. (NASDAQ:PYPD – Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 88,000 shares, a drop of 29.1% from the May 31st total of 124,100 shares. Based on an average daily volume of 112,600 shares, the days-to-cover […]